Clinical Trial News
Temple researchers receive grants to develop ALS therapy, EEG software
December 3, 2013
The University City Science Center in Philadelphia has awarded Temple two proof-of-concept grants: one for the development of a novel therapy for the treatment of amyotrophic lateral sclerosis (ALS) and another for the creation of a software program that will hone physicians’ ability to read and diagnose electroencephalography, or EEGs. Learn more.
First Patient Treated In Phase II Of Neuralstem ALS Stem Cell Trial
September 10th, 2013
Neuralstem, Inc. has announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of ALS at Emory University Hospital in Atlanta, Georgia. Read the Press Release.
Cytokinetics Announces Publication of Results from Phase II Trials of Tirasemtiv in Patients with ALS
August 22nd, 2013
Cytokinetics announced the publication of two manuscripts reporting data from two prior clinical trials of tirasemtiv, highlighting encouraging results. Read the Press Release.
First Regional CRLI Held in Philadelphia, PA
July 15th, 2013
NEALS Executive Committee Member Terry Heiman-Patterson, MD (Drexel University and the ALS Hope Foundation) leads this effort with the goal of providing advocacy training to PALS in and around the surrounding areas. Read more about the event.
NEALS Researcher Featured on CNN Three-Part Series on ALS
June 27th, 2013
Dr. Jeff Rothstein provides medical and research insights during CNN's Three-Part Series on ALS with news anchor Suzanne Malveaux. Learn more
Call for Abstracts - 2013 Annual NEALS Meeting
June 25th, 2013
On behalf of the Executive and Abstract Committees for the 12th Annual NEALS Meeting, we would like to extend an invitation for members to submit an abstract for consideration for presentation at the Annual Meeting.
Nominations for 2013 PALS Clinical Research Learning Institute
June 17th, 2013
The event will take place at the Sandpearl Resort in Clearwater Beach, Florida, on Friday October 4th to Saturday October 5th. The deadline for nominations is August 2nd, 2013. Learn more.
Prize4Life and Knopp Announce Donation of Empower Phase 3 Data to PRO-ACT Database
June 13th, 2013
Knopp Biosciences, Inc. has agreed to donate placebo data from the phase III dexpramipexole trial to the award-winning PRO-ACT Platform, created by the NCRI and Prize4Life in partnership with NEALS. The dataset will be expanded to include treatment-arm data when research into dexpramipexole for ALS is complete. NCRI and NEALS in collaboration with Prize4life will continue to foster encouraging collaborative partnerships between academia and industry via this valuable resource. Read the press release.
Phase IIa ALS Clinical Trial with GM604, a Biotechnology Innovation, has been Approved
May 29th, 2013
Offering imminent hope for those with ALS, Genervon Biopharmaceuticals, an innovative biotechnology company announced today that it has received FDA approval for its broadly inclusive ALS clinical trial. Learn more.
Mass. General Neurological Clinical Research Institute and Prize4Life receive Bio-IT World Award for creation of ALS data platform
April 12th, 2013
The Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI) and Prize4Life received a Best Practices Award at the 2013 Bio-IT World Conference & Expo for the creation of the PRO-ACT platform. Read the press release.
NEALS SOD1 Research is First Antisense Oligonucleotide Trial for a Central Nervous System Disorder
March 29th, 2013
An SOD1-related familial ALS trial under the direction of NEALS researchers Timothy Miller, MD, PhD (Washington University School of Medicine) and Merit Cudkowicz (Massachusetts General Hospital) indicates that antisense oligonucleotide delivery to the central nervous system may be a feasible therapeutic strategy in treating ALS. Read the NEALS Press Release.
NEALS Researcher Receives Award For ALS Research
March 25th, 2013
James D. Berry, MD, MPH, (Massachusetts General Hospital & Harvard Medical School) has received the Richard Olney, MD, Clinician-Scientist Development Award for his investigation of cells in the immune system. Read the AAN press release.
Scientific Advisory Board (SAB) Meets to Brainstorm New Directions for ALS Research
March 8th, 2013
Led by Robert Brown, DPhil, MD (University of Massachusetts) and Jeffery Rothstein, MD, PhD (Johns Hopkins), the SAB met in Boston, MA this past February. Read about the Meeting.
NEALS Executive Committee Election Results
March 7th, 2013
NEALS welcomes Dr. Robert Bowser (Barrow Neurological Institute) and Dr. Tim Miller (Washington University, St. Louis) to the Executive Committee! Read more.
Two New Genes Linked to ALS and Related Disorders
March 3rd, 2013
A study led by St. Jude Children's Research Hospital has discovered mutations in two genes that lead to the death of nerve cells in ALS and related degenerative diseases. Learn more.
US Brainstorm Trial Statement
February 26th, 2013
We have had many inquires regarding the Brainstorm Stem Cell Therapeutics Clinical Trial. Read the US Brainstorm Trial Statement.
FDA is Urged to Expedite ALS Treatments
February 25th, 2013
PALS, caregivers, scientists, and ALS advocates gave their testimonies to a panel of FDA representatives at the first-ever ALS-specific FDA hearing. Speakers pushed for a partnership to get ALS treatments to PALS as fast as possible. Read the ALS Association Press Release.
ALS Drug Development Gets FDA Hearing
February 11th, 2013
PALS, caregivers, ALS advocates and researchers will gather on Monday February 25th to talk to the FDA about ALS, from the patient perspective. Read more.
Phase III Trial of Dexpramipexole (EMPOWER) Results Announced
January 3rd, 2013
Biogen Idec announced phase III EMPOWER trial did not reach its endpoints and did not show efficacy. NEALS Co-Chair Merit Cudkowicz reacts, "While we had all hoped for a positive result, ALS researchers remain truly committed to finding a cure for this disease." Read the Press Release.
NEALS Researcher Highlight: Dr. Terry Heiman-Patterson
December 27th, 2012
Dr. Terry Heiman-Patterson recalls clearly the first individual she diagnosed with ALS as a junior neurology faculty member. It was this encounter which led her to focus her career on improving quality of life for people with ALS and conducting clinical research that might eventually lead to a cure. Read about Dr. Heiman-Patterson.
News from the International Symposium on ALS/MND in Chicago
December 12th, 2012
Scientists from around the world gathered in Chicago, Illinois on December 5-7 2012 to focus on progress in hastening treatments and a cure for Lou Gehrig’s Disease at the 23rd Annual International Symposium on ALS/MND. Read the ALS Association's update.
New Neuralstem Data Presented at MND Meeting
December 10th, 2012
Through DNA fingerprinting, researchers were able to establish long-term survival of Neuralstem's transplanted spinal cord stem cells in autopsied patients. Read more.
Prize4Life Announces the Launch of PRO-ACT: The Largest ALS Clinical Trials Database Ever Created
December 5th, 2012
In partnership with NEALS, Prize4Life and the Neurological Clinical Research Institute at Massachusetts General Hospital have created the largest ALS clinical trial database ever created. Read the Press Release.
NCRI RFP Recipients have been Announced
November 30th, 2012
A Novel Immunosuppression Intervention for the Treatment of ALS and A Clinical Trial of Cogane in Patients with ALS are the two studies selected for this funding. Read the announcement.
The Second Annual Clinical Research Learning Institute was a Success
November 13th, 2012
The CRLI, sponsored by the ALS Association’s TREAT ALS initiative, is an intensive program dedicated to educating patient-caregiver pairs on clinical research and therapy development, while empowering them to be advocates for ALS clinical research, or “Research Ambassadors.” Read about the event.
Prize4Life Announces $50,000 ALS Prediction Prize Winners
November 13th, 2012
Prize4Life, a nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for ALS, has announced 3 winners of its $50,000 DREAM-Phil Bowen ALS Prediction Prize4Life Challenge. Read the Press Release.
ALS Association-Funded Study Finds Blood Protein May Serve as Biomarker to Measure ALS Decline
November 8th, 2012
This study showed that elevated blood levels of a specific protein correlated with more rapid decline in PALS. Read more about the study.
Neuraltus Announces Encouraging Phase II Results
November 6th, 2012
Neuraltus Pharmaceuticals, Inc. has announced results from its phase II clinical study of NP001 in patients with ALS. Results demonstrated that NP001 was safe and well-tolerated. Read more.
Cytokinetics Announces Opening of BENEFIT-ALS
October 29th, 2012
Cytokinetics has announced the opening of BENEFIT-ALS (Blinded Evaluation of Neuromusclar Effects and Functional Improvement with Tirasemtiv in ALS), formerly known as CY 4026, to enrollment.
Read the Press Release.
NCRI Director of Systems Featured in Lab Manager Magazine "Ask the Expert"
October 18th, 2012
Alexander Sherman, director of systems in the Department of Neurology and director of strategic development and systems at the Neurological Clinical Research Institute at Massachusetts General Hospital, discusses why the right choice and setup for data collecting, data handling, and data sharing infrastructure is important to help establish successful research collaborations. Read the article.
NEALS Researcher Highlight: Dr. Timothy Miller
October 3rd, 2012
Timothy Miller’s, MD, PhD interest in exploring neurodegenerative disease began as a graduate student. Learn more about Dr. Miller.
Study Finds NFL Players Four Times More Likely to Get ALS
September 14th, 2012
Alberto Ascherio, MD, DrPH discusses recent findings of ALS in NFL players. Read more.
Cytokinetics Proceeding to Initiate Phase IIb Trial
September 10th, 2012
Cytokinetics plans to initiate this clinical trial, designed to evaluate the safety, tolerability and efficacy of tirasemtiv (formerly CK-2017357) in patients with ALS, in the fourth quarter of 2012.
Read the Press Release.
NEALS Running Team!
August 22nd, 2012
NEALS runners will fundraise to support ongoing NEALS clinical trials. Read how to donate.
NeuRx Diaphragm Pacing System (DPS) Study has been Funded
August 16th, 2012
NEALS will lead a study to assess the ability of the NeuRx Diaphragm Pacing System (DPS) to improve respiratory function and quality of life in people with ALS. Learn more.
Statement on the Clinical Trial of Ceftriaxone
August 8th, 2012
The DSMB for the NINDS-sponsored clinical trial of ceftriaxone in ALS recommended that based on existing data the trial be stopped because the study was unlikely to reach the pre-determined efficacy criteria. Read more.
NEALS Site Cedars-Sinai Medical Center Receives Stem Cell Grant
August 7th, 2012
The California Institute for Regenerative Medicine has awarded a $17.8 million grant to Cedars-Sinai to develop a stem cell treatment for patients with ALS. Learn more.
New Study Suggests that ALS Progression May Be Tracked With Blood Test
August 6th, 2012
According to a new study, funded in part by The ALS Association, published today in the Journal of Clinical Investigation, scientists have identified a biomarker in the blood that signals the earliest stages of the disease. Read more.
US Brainstorm Trial Statement
August 3rd, 2012
We have had many inquires regarding the Brainstorm Stem Cell Therapeutics Clinical Trial.
Read NEALS Statement.
Collaborative Prize Competition May Unlock Mysteries of Disease Progression in PALS
July 11th, 2012
A new Prize4Life Challenge, which consists of predicting future progression of ALS, is based on the PRO-ACT database. Read the Press Release.
Request for Proposals: Clinical development of novel, high-potential treatments for people with ALS
June 29th, 2012
The Neurology Clinical Trials Unit (NCTU) at Massachusetts General Hospital is pleased to announce a call for clinical trial applications for novel, high-potential treatments for ALS. Read the RFP.
Call for Abstracts - 2012 Annual NEALS Meeting
June 19th, 2012
On behalf of the Steering and Abstract Committees for the 11th Annual NEALS Meeting, we would like to extend an invitation for members to submit an abstract for consideration for presentation at the Annual Meeting.
Cytokinetics Announces Results of Phase II Trial of CK-2017357
June 12th, 2012
Published results demonstrated that single oral doses of 250 mg and 500 mg of CK-2017357 appeared safe and well-tolerated in patients with ALS. Read the Press Release.
Results Announced for Phase I Trial of ISIS 333611 in SOD1 FALS
June 11th, 2012
Results indicate that ISIS 333611 was well-tolerated. Read more.
Nominations for 2012 PALS Clinical Research Learning Institute
June 6th, 2012
The event will take place at the Sandpearl Resort in Clearwater Beach, Florida, on Friday October 26th to Saturday October 27th. Deadline for nominations is June 30. Learn more.
NEALS Researcher Highlight: Dr. Robert Bowser
May 15th, 2012
For the past 20 years, Robert Bowser, PhD, has been studying how the regulation of gene expression is involved in neurodegenerative diseases. Learn more about Dr. Bowser.
Current Developments and New Directions Discussed at NEALS Scientific Advisory Board Meeting
May 14th, 2012
The NEALS Scientific Advisory Board (SAB) met this past April. To learn more about the SAB's role,
PRO-ACT Platform to be Accessible to ALS Researchers
May 4th, 2012
NEALS and Prize4Life are developing the PRO-ACT Platform, an ALS clinical trial record database comprised of data collected from Phase II and III trials conducted over the past 20 years.
Cytokinetics Announces Fast Track Designation
April 19th, 2012
The FDA has granted Cytokinetic's drug candidate CK-2017357 a fast track designation for the potential treatment of ALS. This process was designed to expedite the review of drug candidates intended to treat serious conditions. Read the Press Release.
Cogane™ Shown to be Effective in Pre-Clinical Models of ALS
April 18th, 2012
Data from a previously reported study of Cogane™ in a genetic preclinical model of ALS further supports the efficacy of Cogane™. Read the Press Release.
Results From First 12 Participants in Neuralstem Trial Published
April 10th, 2012
Published safety data shows that spinal cord stem cells can be delivered safely into the spines of PALS. Read the Press Release.
2012 Annual Packard Symposium
March 30th, 2012
Investigators from the Robert Packard Center for ALS Research at Johns Hopkins gathered in Baltimore on March 8th-10th for the Center’s annual Scientific Symposium. Read more.
Stem Cell Study Aids Quest for ALS Therapies
March 26th, 2012
An international research team has created motor neurons using skin cells from a person with an inherited form of ALS/MND. Read more.
ALS TDI to Hold TDI 132 Information Webinar on March 12th
February 28th, 2012
The webinar will provide an overview of the scientific rationale for this exciting planned trial as well as discuss the next steps forward. It will be held Monday, March 12th at 3pm Eastern Standard Time. Go here for more details.
ALS TDI to Launch Phase II Trial of TDI 132
February 14th, 2012
TDI 132, also known as Gilenya®, will be investigated for safety and tolerability in patients with ALS. Learn more.
Brainstorm Announces Safety of NurOwn™Treatment
January 17th, 2012
No significant side effects noted in initial Brainstorm participants. Read the Press Release.
Positive Preliminary Results Released by Phytopharm
January 16th, 2012
Cogane has demonstrated efficacy in genetic preclinical model of ALS. Read more.
Biomarkers Study Looking for Participants
January 13th, 2012
Researchers hope to learn more about ALS through patient samples. Read how you can help.
ALS/MND's "Ask the Experts" Forum is Available Online
December 22nd, 2011
Watch the November 28th streamed "Ask the Experts" forum from Sydney, Australia in case you missed it. Learn more.
Results from Phase III Trophos Trial Released
December 14th, 2011
Trophos, a French pharmaceutical company, announced results from its phase III trial of Olesoxime. Read more.
Knopp Announces Positive Phase II Results
November 21st, 2011
Phase II Dexpramipexole, funded by Knopp, shown to be safe and tolerable in patients with ALS. Read the Press Release.
First Annual NEALS Clinical Research Learning Institute Held
November 16th, 2011
NEALS held a meeting in Clearwater, FL for patients and their caregivers to become ALS advocates. Read more.
Ceftriaxone, NP001, and Dexpramipexole Trials Close Enrollment
November 15th, 2011
Phase III trial of Ceftriaxone; Neuraltus, the Phase II study of NP001 in ALS; and EMPOWER, the Phase III study of Dexpramipexole in ALS, are no longer recruiting participants. Read more.
Recipients of NEALS Funding Announced
November 2nd, 2011
The Neurology Clinical Trial Unit at Massachusetts General Hospital and NEALS announced a call for trial applications for high-potential treatments for ALS. Read more.
Alzforum news series about NEALS
November 2nd, 2011
NEALS is in the news! We are excited to announce that the Alzheimer's Research Forum has put together a series of four stories focused on the NEALS Consortium. Read the article.
Most Common Genetic Cause of ALS Discovered
September 30, 2011
Steve Han MD, PhD discusses newly discovered information regarding chromosome 9p21. Read more.
Researchers Discover Common Cause of ALS
August 22nd, 2011
Researchers at Northwestern discovered a new gene linked to familial ALS involved in the processing of accumulated proteins. Read more.
ALS Trial Expert Available to Answer Questions
August 12th, 2011
NEALS and the ALS Association launch a new effort to better provide accurate information about clinical trials. An "Expert" is immediately available help people navigate through clinical research information. Read more.